Shorter radiation before sarcoma surgery: could it reduce wound problems?
NCT ID NCT04946357
First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether a shorter course (2-3 weeks) of proton or carbon ion radiation before surgery for extremity soft tissue sarcoma is safe and feasible. The main goal is to see if it reduces wound healing problems after surgery. The study enrolls 42 adults with resectable sarcoma and compares two types of particle radiation.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- proton or carbon ion radiation
- What this could lead to
- If successful, this could offer a shorter, more convenient radiation schedule before sarcoma surgery with fewer side effects and better wound healing.
- What could go wrong
- This is a small early-phase trial (42 participants) testing safety and feasibility, not yet proven to be better than standard treatment. The results may not apply to all sarcoma patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 42 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2021
- Expected to finish
-
Jul 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed soft-tissue sarcoma of the extremities with an indication for perioperative radiation treatment * Resectable or marginally resectable * Karnofsky index of ≥ 70% * Age ≥ 18 years * Carried out patient education and written consent * Patient is capable to give informed consent Exclusion Criteria: * Stage IV (distant metastases) * Lymph node metastasis * Metal implants that influence treatment planning with ions * Previous radiotherapy in the treatment area * Desmoid tumors * Simultaneous participation in another clinical trial that could influence the results of the study. * Active medical implants for which no ion beam irradiation permit exists at the time of treatment (e.g., cardiac pacemaker, defibrillator)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Soft tissue sarcoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Heidelberg, Department of RadioOncology
Heidelberg, Baden-Wurttemberg, 69120, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a dual immune antibody plus radiation shrink metastatic sarcoma?
- Can a Marine-Derived drug slow advanced soft tissue sarcoma?
- Can a One-Two punch of immunotherapy and radiation tame sarcoma before surgery?
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Could a massive tissue bank unlock sarcoma's secrets?